Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oligomerix has received a program related investment of $100,000 from the Alzheimer's Drug Discovery Foundation.
Subscribe to our email newsletter
The focus of the program is to select compounds using its proprietary Alzheimer’s disease (AD) screening assays active against tau oligomers, and to evaluate these compounds in a tauopathy mouse model.
James Moe, president and CEO of Oligomerix, said: “Tau oligomers play an important role in neurodegeneration and memory loss and are an emerging target for drug discovery for AD. We believe this study will enable the discovery of novel disease-modifying drugs for AD and other tauopathies.”